Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis
- PMID: 36358833
- PMCID: PMC9655334
- DOI: 10.3390/cancers14215415
Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis
Abstract
Angiogenesis in tumor growth and progression involves a series of complex changes in the tumor microenvironment. Extracellular vesicles (EVs) are important components of the tumor microenvironment, which can be classified as exosomes, apoptotic vesicles, and matrix vesicles according to their origins and properties. The EVs that share many common biological properties are important factors for the microenvironmental modification and play a vital role in tumor growth and progression. For example, vascular endothelial growth factor (VEGF) exosomes, which carry VEGF, participate in the tolerance of anti-angiogenic therapy (AAT). The glycocalyx is a mucopolysaccharide structure consisting of glycoproteins, proteoglycans, and glycosaminoglycans. Both endothelial and tumor cells have glycocalyx at their surfaces. Glycocalyx at both cells mediates the secretion and uptake of EVs. On the other hand, many components carried by EVs can modify the glycocalyx, which finally facilitates the development of the tumor microenvironment. In this short review, we first summarize the role of EVs in the development of the tumor microenvironment. Then we review how the glycocalyx is associated with the tumor microenvironment and how it is modulated by the EVs, and finally, we review the role of the glycocalyx in the synthesis, release, and uptake of EVs that affect tumor microenvironments. This review aims to provide a basis for the mechanistic study of AAT and new clues to address the challenges in AAT tolerance, tumor angiogenesis and metastasis.
Keywords: angiogenesis; extracellular vesicles; glycocalyx; metastasis; microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Extracellular vesicles in tumor angiogenesis and resistance to anti-angiogenic therapy.Cancer Sci. 2023 Jul;114(7):2739-2749. doi: 10.1111/cas.15801. Epub 2023 Apr 12. Cancer Sci. 2023. PMID: 37010195 Free PMC article. Review.
-
Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling.Cell Commun Signal. 2022 Jun 25;20(1):97. doi: 10.1186/s12964-022-00904-5. Cell Commun Signal. 2022. PMID: 35752798 Free PMC article. Review.
-
Cell-specific targeting of extracellular vesicles through engineering the glycocalyx.J Extracell Vesicles. 2022 Dec;11(12):e12290. doi: 10.1002/jev2.12290. J Extracell Vesicles. 2022. PMID: 36463392 Free PMC article.
-
Involvement of Extracellular Vesicles in Vascular-Related Functions in Cancer Progression and Metastasis.Int J Mol Sci. 2019 May 26;20(10):2584. doi: 10.3390/ijms20102584. Int J Mol Sci. 2019. PMID: 31130715 Free PMC article. Review.
-
Extracellular Vesicles Are Key Regulators of Tumor Neovasculature.Front Cell Dev Biol. 2020 Dec 9;8:611039. doi: 10.3389/fcell.2020.611039. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33363175 Free PMC article. Review.
Cited by
-
Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance.Front Physiol. 2023 Jun 14;14:1199225. doi: 10.3389/fphys.2023.1199225. eCollection 2023. Front Physiol. 2023. PMID: 37389120 Free PMC article. Review.
-
Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?Skin Health Dis. 2025 Apr 22;5(2):102-113. doi: 10.1093/skinhd/vzaf022. eCollection 2025 Apr. Skin Health Dis. 2025. PMID: 40365251 Free PMC article. Review.
-
Destruction of vascular endothelial glycocalyx during formation of pre-metastatic niches.Heliyon. 2024 Apr 1;10(7):e29101. doi: 10.1016/j.heliyon.2024.e29101. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38601565 Free PMC article.
-
Deciphering the Blood-Brain Barrier Paradox in Brain Metastasis Development and Therapy.Cancers (Basel). 2025 Jan 17;17(2):298. doi: 10.3390/cancers17020298. Cancers (Basel). 2025. PMID: 39858080 Free PMC article. Review.
-
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.Vaccines (Basel). 2023 Feb 10;11(2):408. doi: 10.3390/vaccines11020408. Vaccines (Basel). 2023. PMID: 36851285 Free PMC article. Review.
References
-
- Cacheux W., Boisserie T., Staudacher L., Vignaux O., Dousset B., Soubrane O., Terris B., Mateus C., Chaussade S., Goldwasser F. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2008;19:1659–1661. doi: 10.1093/annonc/mdn540. - DOI - PubMed
-
- Becherirat S., Valamanesh F., Karimi M., Faussat A.M., Launay J.M., Pimpie C., Therwath A., Pocard M. Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes. Transl. Oncol. 2018;11:406–415. doi: 10.1016/j.tranon.2018.01.017. - DOI - PMC - PubMed
-
- Griffioen A.W., Mans L.A., de Graaf A.M.A., Nowak-Sliwinska P., de Hoog C., de Jong T.A.M., Vyth-Dreese F.A., van Beijnum J.R., Bex A., Jonasch E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012;18:3961–3971. doi: 10.1158/1078-0432.CCR-12-0002. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous